Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.
Seniz OngorenAhmet Emre EskazanVeysel SuzanSercan SavciIsil Erdogan OzunalSelin BerkFevzi Fırat YalnizTugrul ElverdiAyse SalihogluYucel ErbilginSibel Aylin IseriMuhlis Cem ArZafer BaslarYildiz AydinNukhet TuzunerUgur OzbekTeoman SoysalPublished in: Hematology (Amsterdam, Netherlands) (2017)
In patients failing two lines of TKI, dasatinib or nilotinib can be beneficial and safely administered as a third-line treatment especially in nations with restricted resources.